Know Cancer

or
forgot password

Treatment Use Study of CP-675,206 for Advanced Melanoma


Phase 3
18 Years
N/A
Not Enrolling
Both
Advanced Unresectable Melanoma

Thank you

Trial Information

Treatment Use Study of CP-675,206 for Advanced Melanoma


This is an expanded access trial that canceled prior to enrolling patients.


Inclusion Criteria:



- Advanced melanoma with life expectancy of at least 6 months.

- Melanoma must be considered unresectable.

- Patients with stable, treated brain mets must be stable clinically and
radiographically and off steroids for at least one month.

Exclusion Criteria:

- Patients must not be eligible for participation in any ongoing CP-675,206 clinical
studies currently open for enrollment.

- History of chronic inflammatory or autoimmune disease.

- History of inflammatory bowel disease, celiac disease, or other chronic
gastrointestinal conditions associated with diarrhea, active colitis, history of
diverticulitis.

Type of Study:

Expanded Access

Study Design:

N/A

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A3671028

NCT ID:

NCT00584493

Start Date:

May 2008

Completion Date:

Related Keywords:

  • Advanced Unresectable Melanoma
  • Melanoma

Name

Location